NDAOPHTHALMIC, OTICOINTMENT
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
HYDELTRASOL (prednisolone sodium phosphate) by Merck & Co. is clinical pharmacology naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDELTRASOL (Prednisolone Sodium Phosphate) is a synthetic glucocorticoid steroid administered as an ophthalmic and otic ointment formulation. It works by suppressing inflammatory processes, inhibiting immune cell production, and stabilizing cell membranes to reduce edema, capillary dilatation, and leukocyte migration. The drug is indicated for corticosteroid-responsive inflammatory conditions of the eye and ear.
Pre-Launch
Pre-launch lifecycle indicates active commercial planning and team building phases; opportunity to shape go-to-market strategy and early market positioning.
Mechanism of Action
CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many…
Worked on HYDELTRASOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.